EyeBio doubles the size of its Series A as anti-VEGF veterans seek new ways of treating retinal diseases
14 Nov 2023
Retinal disease biotech EyeBio has doubled the size of its initial Series A raise from February 2022. With another $65 million, the biotech will further test its Wnt agonist and bring a second asset into the clinic next year, CEO David Guyer told Endpoints News on Tuesday morning.
The Series A extension arrives a few weeks after the field’s biggest confab, the American Academy of Ophthalmology annual meeting, and comes after a string of financing rounds that has buoyed other startups in the space.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.